Investment in new premises to create increase in cutting-edge genomic solutions and collaborative partnerships.
Read articleInvestment in new premises to create increase in cutting-edge genomic solutions and collaborative partnerships.
ReadNew NGS assay delivers exceptional coverage, providing a rapid and highly sensitive means of investigating MRD in AML samples
ReadFuelled by cutting-edge clinical and genomic data, partnership provides intuitive and fully customisable reporting capabilities for all conditions
ReadCollaboration will enable users to readily and simply interpret variant calls made by OGT’s NGS software via the Intelliseq iFlow™ engine.
ReadOGT becomes Britain’s distributor for ASI cytogenetic imaging and analysis solutions, enhancing the potential of OGT’s CytoCell® FISH portfolio.
ReadCompany demonstrates complete readiness for new EU IVDR and continued confidence in its safe, reliable, high-quality products.
ReadEnhanced NGS portfolio includes Interpret Software updates and enables rapid and confident variant detection even in difficult-to-sequence regions.
ReadExpansion of access to clinical support network and market-leading genomic solutions aims to improve patient outcomes.
ReadNew leadership will drive OGT’s mission to improve clinical care by partnering with customers.
ReadCytoCell® University offers extensive FISH expertise and reaffirms commitment to customer support and training.
ReadNew integrated website, expanded resources and substantial worldwide support reaffirm partnership and commitment to customers.
ReadIn the workshop users will explain how OGT’s SureSeq™ NGS panels can increase throughput and save time and cost in the detection of a wide variety of aberrations.
Read
Visit USA site
Visit Canada site
